Trial site
Azienda Unita Sanitaria Locale Della Romagna
Faenza, 48018, ItalyNot linked to an institution yet
- 16running trials
- 10closed trials
The trials here
What the 26 trials at this site are about, from their registry records.
- Phase
- Phase 316 trials
- Phase 28 trials
- Phase 1/22 trials
- Status
- Completed10 trials
- Active, not recruiting9 trials
- Recruiting6 trials
- Not yet recruiting1 trial
- Lead sponsor
- Anthos Therapeutics, Inc.3 trials
- F. Hoffmann-La Roche AG2 trials
- Fondazione IRCCS Istituto Nazionale Dei Tumori2 trials
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS2 trials
- Hoffmann-La Roche2 trials
- and 15 more
Running trials
Recruiting
“A Phase II trial of atezolizumab plus CArboplatin plus nab-Paclitaxel as first-line Therapy in metastatic triple-negative PD-L1 positive breast cancer patients”
2024-519514-31-00· Phase 2· Consorzio Oncotech· Source
Active, not recruiting
Study on the combination of two immunotherapeutic agents as pre-surgical therapy or definitive treatment in patients with resectable gastric or gastroesophageal junction cancer with microsatellite instability.
2024-518842-26-00· Phase 2· Fondazione GONO G.I.· Source
Active, not recruiting
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, fallopian tube and primitive peritoneal cancer
NCT05233982· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· Phase 3· Hoffmann-La Roche· Source
Recruiting
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
NCT05712200· Phase 3· Anthos Therapeutics, Inc.· Source
Recruiting
Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study
2024-515681-14-00· Phase 2· Fondazione IRCCS Istituto Nazionale Dei Tumori· Source
Active, not recruiting
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547· Phase 3· ARCAGY/ GINECO GROUP· Source
Active, not recruiting
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
NCT04564898· Phase 1/2· Gruppo Oncologico del Nord-Ovest· Source
Recruiting
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
NCT05255471· Phase 3· National Cancer Institute, Naples· Source
Recruiting
Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer
NCT05136326· Phase 2· Fondazione IRCCS Istituto Nazionale dei Tumori, Milano· Source
Active, not recruiting
MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination.
2024-516632-99-00· Phase 2· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source
Recruiting
Phase 1b/2 trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.
2024-515580-64-00· Phase 1/2· Fondazione IRCCS Istituto Nazionale Dei Tumori· Source
Recruiting
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
NCT04257487· Phase 3· Arianna Anticoagulazione Foundation· Source
Active, not recruiting
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03937219· Phase 3· Exelixis· Source
Active, not recruiting
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
NCT02319837· Phase 3· Pfizer· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy
2023-506696-10-00· Phase 3· F. Hoffmann-La Roche AG· Source
Active, not recruiting
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
NCT05609578· Phase 2· Mirati Therapeutics Inc.· Source
Terminated
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
NCT05171075· Phase 3· Anthos Therapeutics, Inc.· Source
Terminated
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE
NCT05171049· Phase 3· Anthos Therapeutics, Inc.· Source
Active, not recruiting
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer
NCT05091567· Phase 3· Hoffmann-La Roche· Source
Completed
Prospective, non randomized, Phase II study on MK-3475 in recurrent, platinum-resistant, CPS ≥1 positive ovarian, Fallopian tube and primary peritoneal cancer patients
2024-516629-30-00· Phase 2· Fondazione Policlinico Universitario Agostino Gemelli IRCCS· Source
Completed
Phase 3 Study of Pembrolizumab and Lenvatinib in Combination with TACE for Incurable/Non-metastatic Hepatocellular Carcinoma
NCT04246177· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)
2023-505035-12-00· Phase 3· F. Hoffmann-La Roche AG· Source
Completed
A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
NCT03656536· Phase 3· Incyte Corp.· Source
Active, not recruiting
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· Phase 3· Tesaro, Inc.· Source
Report an error